Latest News Archive

Please select Category, Year, and then Month to display items
Years
2017 2018 2019 2020
Previous Archive
14 June 2018 Photo Supplied
Next Chapter Green Ribbon campaign addresses mental health
Members of Next Chapter and UFS Student counselling are working together to address mental health issues.

Next Chapter, a student support group at the UFS presented the Green Ribbon campaign, pledging their support to students and providing them with assistance in coping with life events that stimulate stress and contribute negatively to their mental health. The team aims to break the stigma surrounding mental health care, and continually assist students with mental health-related issues that they struggle with daily.

The Green Ribbon represents mental health awareness, which is a pressing matter for students and is the type of support students need in a stressful university environment. The campaign focuses on teaching students how to cope with life events that stimulate stress, and contribute negatively to their mental health.
 
A discussion by Dr Ancel George: practising clinical psychologist and lecturer from the UFS Department of Psychology, and Dr Mellissa Barnaschone: Director of UFS Student Counselling, took place, where talks were prominent about creating an inclusive environment for UFS students.

The panel shared a few tips on how students should work towards managing stress, and motivated them for the main mid-year examinations.
 
The follow-up Exam Cram Workshop, presented by Nadia Cloete and Lize Wolmarans, that combined time and stress management, took place on 2 June 2018, and saw students receiving advice on how to approach various issues during the examination period.
 
Mental health awareness does not end with the campaign and Next Chapter’s slogan “Your story continues” encourages students to regularly wear and commemorate the green ribbon in support of continual mental healthcare.
 
Should you have any enquiries or input for the ongoing campaign, contact the Next Chapter team on ufsnextchapter@gmail.com, or further email Tshepang Mahlatsi, founder of Next Chapter on tshepangmahlatsi767@gmail.com

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept